3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Head & Neck
3
Sarcoma
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-mutant Non-Small Cell Lung Cancer
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
7
pembrolizumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Cisplatin
3
Vorinostat
2
Taxes
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Gene Expression Profiling
2
Filgrastim
2
Cetuximab
2
Biopsy
2
zanidatamab
1
vandetanib
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
talactoferrin alfa
1
spartalizumab
1
sargramostim
1
pertuzumab
1
neratinib
1
larotrectinib
1
fluoromisonidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
trastuzumab deruxtecan
×
Thoracic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled